Cantor Fitzgerald Predicts VYGR FY2026 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Voyager Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings per share of ($1.40) for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.18). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $6.47 million during the quarter, compared to the consensus estimate of $13.55 million.

A number of other analysts have also recently issued reports on the company. Wedbush restated an "outperform" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group lowered their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 13th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Finally, Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the company an "overweight" rating in a research report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $13.39.

Voyager Therapeutics Stock Down 8.3%

Voyager Therapeutics stock traded down $0.30 during trading hours on Tuesday, hitting $3.30. The stock had a trading volume of 913,503 shares, compared to its average volume of 477,275. The company has a 50-day moving average of $3.26 and a two-hundred day moving average of $4.38. Voyager Therapeutics has a fifty-two week low of $2.65 and a fifty-two week high of $9.55. The company has a market cap of $182.61 million, a PE ratio of 4.65 and a beta of 0.82.

Institutional Trading of Voyager Therapeutics

Large investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP raised its stake in shares of Voyager Therapeutics by 151.0% in the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company's stock valued at $6,974,000 after acquiring an additional 740,000 shares during the last quarter. AQR Capital Management LLC raised its position in Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock valued at $1,674,000 after purchasing an additional 317,927 shares during the last quarter. Farallon Capital Management LLC boosted its stake in Voyager Therapeutics by 12.2% in the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company's stock worth $14,576,000 after purchasing an additional 278,700 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Voyager Therapeutics by 24.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company's stock worth $7,828,000 after purchasing an additional 275,571 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Voyager Therapeutics by 863.3% during the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after purchasing an additional 206,758 shares during the last quarter. 48.03% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the transaction, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at $1,478,093.33. This trade represents a 2.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 6.39% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.